• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    89 Biggest Movers From Friday

    6/21/22 4:44:52 AM ET
    $ADN
    $ADXN
    $AKRO
    $ALLK
    Industrial Machinery/Components
    Miscellaneous
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADN alert in real time by email

    Gainers

    • Revlon, Inc. (NYSE:REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
    • Grove Collaborative Holdings, Inc. (NYSE:GROV) rose 67.9% to close at $10.00. Grove Collaborative and Virgin Group Acquisition Corp. II announced the completion of their previously announced business combination.
    • Mereo BioPharma Group plc (NASDAQ:MREO) gained 62.5% to close at $1.30. AstraZeneca is rumored to be eyeing takeover of Mereo BioPharma Group, according to a report in The Times.
    • SoundHound AI, Inc. (NASDAQ:SOUN) climbed 49.8% to close at $4.44.
    • Swvl Holdings Corp. (NASDAQ:SWVL) gained 35.3% to settle at $6.90.
    • Clovis Oncology, Inc. (NASDAQ:CLVS) surged 31.9% to close at $1.18. Clovis Oncology recently announced a presentation detailing initial Phase 1 data from Phase 1/2 LuMIERE clinical study of FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).
    • Jupiter Wellness, Inc. (NASDAQ:JUPW) jumped 31.4% to close at $0.80. Jupiter Wellness retired approximately 10% of its outstanding shares.
    • Satellogic Inc. (NASDAQ:SATL) jumped 29.6% to close at $5.04.
    • Electric Last Mile Solutions, Inc. (NASDAQ:ELMS) gained 29.4% to close at $0.3650 after jumping 100% on Thursday.
    • Sesen Bio, Inc. (NASDAQ:SESN) climbed 29.2% to close at $0.76.
    • Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) jumped 28.8% to close at $0.3002.
    • Virgin Orbit Holdings, Inc. (NASDAQ:VORB) gained 28.1% to close at $3.51.
    • Cipher Mining Inc. (NASDAQ:CIFR) gained 27.3% to settle at $1.82.
    • Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) gained 26.9% to close at $4.44. Comera was granted U.S. patent titled 'Excipient compounds for protein processing.'
    • Clear Channel Outdoor Holdings, Inc. (NYSE:CCO) jumped 26.6% to settle at $1.38.
    • Tivic Health Systems, Inc. (NASDAQ:TIVC) rose 26.3% to close at $2.40. Tivic Health Systems, during May, reported a Q1 loss of $0.23 per share.
    • Starry Group Holdings, Inc. (NYSE:STRY) gained 26% to close at $5.18. Cowen & Co. initiated coverage on Starry Group Holdings with an Outperform rating and announced a price target of $9.
    • XpresSpa Group, Inc. (NASDAQ:XSPA) gained 24.6% to close at $0.86.
    • Secoo Holding Limited (NASDAQ:SECO) rose 24% to settle at $0.2874. Secoo received approval to transfer to Nasdaq Capital Market.
    • Symbotic Inc. (NASDAQ:SYM) gained 23.8% to close at $16.80.
    • Altimmune, Inc. (NASDAQ:ALT) surged 22.9% to settle at $9.02.
    • Pharvaris N.V. (NASDAQ:PHVS) jumped 22.1% to close at $27.50.
    • Virco Mfg. Corporation (NASDAQ:VIRC) gained 21.9% to close at $3.67.
    • MINISO Group Holding Limited (NYSE:MNSO) climbed 21.8% to close at $7.67.
    • Sana Biotechnology, Inc. (NASDAQ:SANA) gained 21.5% to close at $5.15.
    • Jerash Holdings (US), Inc. (NASDAQ:JRSH) jumped 20.2% to settle at $6.70. Jerash Holdings’ board recently authorized a $3 million buyback.
    • Crexendo, Inc. (NASDAQ:CXDO) surged 20.1% to settle at $3.23.
    • Lyell Immunopharma, Inc. (NASDAQ:LYEL) jumped 20% to close at $5.46.
    • PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) rose 19.8% to close at $0.6201.
    • Zai Lab Limited (NASDAQ:ZLAB) jumped 19.8% to close at $27.73. Zai Lab recently announced breakthrough therapy designations granted for Repotrectinib in China.
    • Rocky Mountain Chocolate Factory, Inc. (NASDAQ:RMCF) jumped 19.6% to settle at $8.25. Rocky Mountain Chocolate, last month, posted Q4 EPS of $0.01.
    • Centessa Pharmaceuticals plc (NASDAQ:CNTA) gained 19.1% to close at $4.93 after BRMO Capital initiated coverage on the stock with an Outperform rating and $19 price target.
    • Sonder Holdings Inc. (NASDAQ:SOND) surged 18.8% to close at $1.52.
    • Helbiz, Inc. (NASDAQ:HLBZ) climbed 18.6% to close at $0.83.
    • REE Automotive Ltd. (NASDAQ:REE) jumped 18.6% to close at $1.53.
    • Rubius Therapeutics, Inc. (NASDAQ:RUBY) gained 18.4% to settle at $0.9323.
    • Lilium N.V. (NASDAQ:LILM) gained 18% to close at $2.69.
    • Heritage Global Inc. (NASDAQ:HGBL) jumped 17.8% to close at $1.55.
    • Cogent Biosciences, Inc. (NASDAQ:COGT) jumped 17.8% to close at $9.19. Cogent Biosciences recently announced a proposed public offering of $125 million of common stock.
    • Q&K International Group Limited (NASDAQ:QK) gained 17.7% to settle at $1.60.
    • Velocity Financial, Inc. (NYSE:VEL) rose 17.6% to close at $11.64.
    • BridgeBio Pharma, Inc. (NASDAQ:BBIO) gained 17.5% to close at $7.65.
    • Mersana Therapeutics, Inc. (NASDAQ:MRSN) jumped 17.5% to close at $3.70.
    • Akero Therapeutics, Inc. (NASDAQ:AKRO) surged 17.3% to settle at $12.16. Akero Therapeutics announced a $25 million equity investment by Pfizer at $9.90 per share.
    • Quotient Limited (NASDAQ:QTNT) gained 17.2% to settle at $0.3599.
    • Dyne Therapeutics, Inc. (NASDAQ:DYN) rose 17.2% to close at $5.94.
    • Synlogic, Inc. (NASDAQ:SYBX) surged 16.6% to close at $1.04.
    • Bit Digital, Inc. (NASDAQ:BTBT) jumped 16.4% to close at $1.42.
    • Allogene Therapeutics, Inc. (NASDAQ:ALLO) gained 16.4% to close at $ 10.96.
    • Allogene Therapeutics recently said that the FDA granted regenerative medicine advanced therapy designation to ALLO-501A for Large B Cell Lymphoma.
    • Stem, Inc. (NYSE:STEM) rose 16.4% to settle at $7.30.
    • bluebird bio, Inc. (NASDAQ:BLUE) shares gained 16.3% to close at $3.56. The FDA's Advisory Committee recently unanimously backed Bluebird bio’s gene therapy for a rare blood disorder.
    • Atara Biotherapeutics, Inc. (NASDAQ:ATRA) rose 16.2% to close at $5.87.
    • Scopus BioPharma Inc. (NASDAQ:SCPS) jumped 15.9% to settle at $0.4250.
    • Vaxart, Inc. (NASDAQ:VXRT) gained 15.6% to close at $3.12.
    • Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) jumped 15.3% to close at $7.62.
    • Allakos Inc. (NASDAQ:ALLK) gained 14.2% to close at $2.97.
    • Kinnate Biopharma Inc. (NASDAQ:KNTE) rose 13.7% to close at $9.36.
    • Seagen Inc. (NASDAQ:SGEN) shares rose 12.7% to close at $165.45. Merck is eyeing purchase of biotech Seagen, while other unnamed suitors are also eyeing Seagen, the Wall Street Journal said.
    • Calliditas Therapeutics AB (NASDAQ:CALT) rose 12% to close at $17.82.
    • Scholar Rock Holding Corporation (NASDAQ:SRRK) shares rose 10.9% to close at $5.39. Scholar Rock reported Phase 2 topaz trial extension data showing 'sizable and sustained motor function improvement at 24 months with apitegromab for non-ambulatory patients with types 2 and 3 spinal muscular atrophy.'
    • Sapiens International Corporation N.V. (NASDAQ:SPNS) climbed 10.9% to close at $23.22.
    • Sight Sciences, Inc. (NASDAQ:SGHT) jumped 10.4% to close at $8.27.
    • Surrozen, Inc. (NASDAQ:SRZN) gained 8.6% to close at $2.41. Surrozen recently initiated dosing in Phase 1 clinical trial of SZN-043 for severe alcoholic hepatitis.

     


    Losers

    • Renovare Environmental, Inc (NASDAQ:RENO) fell 64.7% to close at $0.06 on Friday.
    • Addex Therapeutics Ltd (NASDAQ:ADXN) shares declined 58.3% to settle at $1.50 after the company terminated its Phase 2b/3 study of Dipraglurant for dyskinesia associated with Parkinson's disease due to slow recruitment. The company suspended its guidance amid the termination.
    • ToughBuilt Industries, Inc. (NASDAQ:TBLT) fell 51.5% to close at $1.48 after the company priced a $6 million offering.
    • Advent Technologies Holdings, Inc. (NASDAQ:ADN) declined 27.6% to close at $2.89. Advent Technologies recently announced it received notification of euro 782.1 million of funding from the Greek State for the IPCEI Green HiPo project.
    • Bon Natural Life Limited (NASDAQ:BON) fell 23% to close at $2.85.
    • Axcella Health Inc. (NASDAQ:AXLA) dropped 22.7% to close at $1.80.
    • Pennsylvania Real Estate Investment Trust (NYSE:PEI) shares declined 20.5% to close at $4.23.
    • Sidus Space, Inc. (NASDAQ:SIDU) fell 19.3% to close at $6.16.
    • Equillium, Inc. (NASDAQ:EQ) declined 16.7% to settle at $1.75.
    • NeuroPace, Inc.(NASDAQ:NPCE) fell 16% to close at $5.03.
    • Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) dropped 15.7% to close at $2.42.
    • Innate Pharma S.A. (NASDAQ:IPHA) fell 15.3% to close at $2.00.
    • Applied UV, Inc. (NASDAQ:AUVI) declined 15.2% to close at $2.45.
    • AN2 Therapeutics, Inc. (NASDAQ:ANTX) fell 15.1% to settle at $8.51.
    • Neptune Wellness Solutions Inc. (NASDAQ:NEPT) declined 14.7% to close at $2.32. Neptune Wellness appointed Raymond Silcock as Chief Financial Officer.
    • Vertex Energy, Inc. (NASDAQ:VTNR) fell 14.5% to settle at $11.82.
    • Mesa Royalty Trust (NYSE:MTR) declined 14.5% to close at $14.96.
    • Northern Oil and Gas, Inc. (NYSE:NOG) fell 14.4% to close at $27.52.
    • Hillstream BioPharma, Inc. (NASDAQ:HILS) dropped 14.4% to close at $0.78.
    • Alvotech Ordinary Shares (NASDAQ:ALVO) fell 14.1% to close at $9.70.
    • Heart Test Laboratories, Inc. (NASDAQ:HSCS) dropped 14.1% to close at $2.0777. Heart Test Laboratories announced pricing of its IPO of 1.5 million units at a price of $4.25 per unit.
    • Athersys, Inc. (NASDAQ:ATHX) fell 12.9% to close at $0.2789 after dropping more than 12% on Thursday.
    • Calumet Specialty Products Partners, L.P. (NASDAQ:CLMT) declined 12.1% to close at $10.15.
    • Vivakor, Inc. (NASDAQ:VIVK) fell 10.4% to close at $2.23. Vivakor shares jumped 40% on Thursday after the company announced it signed a definitive agreement to acquire Silver Fuels Delhi and White Claw Colorado City.
    • Dream Finders Homes, Inc. (NASDAQ:DFH) dipped 10% to close at $10.64. B of A Securities downgraded Dream Finders Homes from Neutral to Underperform and lowered the price target from $18 to $10.5.
    • Range Resources Corporation (NYSE:RRC) fell 9.9% to close at $26.29.
    Get the next $ADN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADN
    $ADXN
    $AKRO
    $ALLK

    CompanyDatePrice TargetRatingAnalyst
    BridgeBio Pharma Inc.
    $BBIO
    1/28/2026$157.00Overweight
    Barclays
    Altimmune Inc.
    $ALT
    1/28/2026$20.00Overweight
    Barclays
    Satellogic Inc.
    $SATL
    1/21/2026$5.00Buy
    Craig Hallum
    Range Resources Corporation
    $RRC
    1/16/2026$38.00Buy → Neutral
    BofA Securities
    Atara Biotherapeutics Inc.
    $ATRA
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    Range Resources Corporation
    $RRC
    1/12/2026$43.00Overweight → Equal Weight
    Wells Fargo
    Scholar Rock Holding Corporation
    $SRRK
    1/9/2026$55.00Buy
    Citigroup
    Allogene Therapeutics Inc.
    $ALLO
    1/9/2026$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    More analyst ratings

    $ADN
    $ADXN
    $AKRO
    $ALLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on BridgeBio Pharma with a new price target

    Barclays initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $157.00

    1/28/26 7:16:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Altimmune with a new price target

    Barclays initiated coverage of Altimmune with a rating of Overweight and set a new price target of $20.00

    1/28/26 7:15:18 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum initiated coverage on Satellogic with a new price target

    Craig Hallum initiated coverage of Satellogic with a rating of Buy and set a new price target of $5.00

    1/21/26 8:14:53 AM ET
    $SATL
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ADN
    $ADXN
    $AKRO
    $ALLK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $202,534 worth of shares (9,357 units at $21.65) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/3/26 8:03:54 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Global Value Investment Corp. bought $22,353 worth of shares (11,300 units at $1.98) (SEC Form 4)

    4 - Rocky Mountain Chocolate Factory, Inc. (0001616262) (Issuer)

    1/22/26 9:55:04 PM ET
    $RMCF
    Specialty Foods
    Consumer Staples

    Interim CEO Geygan Jeffrey Richart bought $22,353 worth of shares (11,300 units at $1.98) (SEC Form 4)

    4 - Rocky Mountain Chocolate Factory, Inc. (0001616262) (Issuer)

    1/22/26 9:55:05 PM ET
    $RMCF
    Specialty Foods
    Consumer Staples

    $ADN
    $ADXN
    $AKRO
    $ALLK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gibson Christopher converted options into 40,000 shares, sold $164,800 worth of shares (40,000 units at $4.12), was granted 30,346 shares and covered exercise/tax liability with 10,364 shares, increasing direct ownership by 2% to 933,821 units (SEC Form 4)

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    2/6/26 5:53:41 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Borgeson Blake sold $924,000 worth of shares (220,000 units at $4.20), decreasing direct ownership by 3% to 6,429,863 units (SEC Form 4)

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    2/6/26 5:53:34 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Invus Global Management, Llc exercised 1,575,008 in-the-money shares at a strike of $7.35 (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    2/6/26 5:35:54 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADN
    $ADXN
    $AKRO
    $ALLK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

    Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

    11/25/24 8:41:11 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for RUBRACA issued to CLOVIS ONCOLOGY INC

    Submission status for CLOVIS ONCOLOGY INC's drug RUBRACA (SUPPL-13) with active ingredient RUCAPARIB CAMSYLATE has changed to 'Approval' on 12/21/2022. Application Category: NDA, Application Number: 209115, Application Classification: Efficacy

    12/22/22 4:37:40 AM ET
    $CLVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $ADXN
    $AKRO
    $ALLK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bit Digital Inc. Reports Monthly Ethereum Treasury and Staking Metrics for January 2026

    NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Bit Digital, Inc. (NASDAQ:BTBT) ("Bit Digital" or the "Company") today announced its monthly Ethereum ("ETH") treasury and staking metrics for the month of January 2026: Key Highlights for January 2026 As of January 31, 2026, the Company held approximately 155,239.4[1] ETH.Based on a closing ETH price of approximately $2,449, as of January 31, 2026, the market value of the Company's ETH holdings was approximately $380.2 million.The Company's total average ETH acquisition price for all holdings was approximately $3,045 as of January 31, 20

    2/6/26 8:00:00 AM ET
    $BTBT
    $WYFI
    Finance: Consumer Services
    Finance

    Surrozen to Present at Upcoming Healthcare Investor Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 Presentation at 1:30 PM Eastern Time / 10:30 AM Pacific Time Interested parties may access the live audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surr

    2/5/26 4:05:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $207B Market Shift: The Race for Fast Track Approval in Oncology

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 5, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The FDA isn't just approving drugs; they are completely reshaping the landscape. In 2025 alone, the agency issued over 50 oncology approvals[1], but the real story is the aggressive pivot toward targeted therapies for high-unmet-need solid tumors. That momentum has accelerated in 2026 with a sudden flurry of expedited designations[2] for RAS inhibitors and rare malignancies. This regulatory velocity creates a clear validation framework, positioning Oncolytics Biotech Inc. (NASDAQ:ONCY), Relay Therapeutics (NASDAQ:RLAY), MAIA Biotechnology (NYSE-A: MAIA), Zai Lab (NASDAQ:

    2/5/26 9:35:00 AM ET
    $AVBP
    $ONCY
    $RLAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ADN
    $ADXN
    $AKRO
    $ALLK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Equillium Inc.

    SCHEDULE 13G/A - Equillium, Inc. (0001746466) (Subject)

    2/6/26 4:32:05 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Altimmune Inc.

    S-8 - Altimmune, Inc. (0001326190) (Filer)

    2/6/26 4:07:05 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Centessa Pharmaceuticals plc

    SCHEDULE 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

    2/6/26 1:11:50 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $ADXN
    $AKRO
    $ALLK
    Leadership Updates

    Live Leadership Updates

    View All

    Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors

    BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, effective January 1, 2026. Dr. Incerti is a highly accomplished executive with a strong background in medicine and over 35 years of strategic experience in the biopharmaceutical industry. "Carlo's appointment comes at a pivotal moment for Sparrow as we are looking ahead to pivotal trials of clofutriben for type 2 diabetes and seeking to expand development into other cardiometabolic indications," said Robert Jacks, Sparrow President and Chief Executive Officer. "Carlo is respected globally for

    2/2/26 8:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NN, Inc. Appoints Ted White to Board of Directors

    CHARLOTTE, N.C., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NN, Inc. ("NN" or the "Company") (NASDAQ:NNBR), a global diversified industrial company that engineers and manufactures high-precision components and assemblies, today announced that it has appointed Ted White to its Board of Directors (the "Board"), effective immediately. In connection with this appointment, the Company has entered into a cooperation agreement (the "Cooperation Agreement") with Legion Partners Asset Management, LLC (together with its affiliates, "Legion"), one of the Company's largest shareholders. Mr. White, Legion's co-founder and Managing Director, is an experienced institutional investor and has corporate governance

    1/20/26 8:00:00 AM ET
    $CCO
    $NNBR
    Advertising
    Consumer Discretionary
    Industrial Machinery/Components
    Industrials

    REE Automotive Announces Appointment of Former Chairman and CEO of Hitachi America, Hicham Abdessamad, as Chairman of the Board of Directors

    TEL AVIV, Israel, Jan. 07, 2026 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (NASDAQ:REE), a leading automotive technology company and provider of full by-wire electric vehicle platforms and software-enabled mobility solutions, today announced that Hicham Abdessamad has been appointed Chairman of its Board of Directors, effective December 22, 2025. Mr. Abdessamad succeeds Carlton Rose, who has served as Chairman of the Board since 2023. Mr. Rose will continue to serve as a member of REE's Board of Directors following the transition of the Chair role to Mr. Abdessamad. Mr. Abdessamad has served on REE's Board of Directors since March 29, 2023. He brings deep strategic leadership and extensive

    1/7/26 12:00:00 PM ET
    $REE
    Auto Manufacturing
    Industrials

    $ADN
    $ADXN
    $AKRO
    $ALLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Clear Channel Outdoor Holdings Inc.

    SC 13D/A - Clear Channel Outdoor Holdings, Inc. (0001334978) (Subject)

    12/4/24 5:00:38 PM ET
    $CCO
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Rocky Mountain Chocolate Factory Inc.

    SC 13D/A - Rocky Mountain Chocolate Factory, Inc. (0001616262) (Subject)

    11/29/24 2:00:08 PM ET
    $RMCF
    Specialty Foods
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Satellogic Inc.

    SC 13D/A - Satellogic Inc. (0001874315) (Subject)

    11/27/24 4:30:03 PM ET
    $SATL
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ADN
    $ADXN
    $AKRO
    $ALLK
    Financials

    Live finance-specific insights

    View All

    Vivakor Signs Letter of Intent to Sell its Midstream Business in Oklahoma STACK Play for $36 Million to Olenox Industries

    Dallas, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTC:VIVK) ("Vivakor" or the "Company"), an integrated provider of energy transportation, storage, reuse, and remediation service, today announced that it has executed a non-binding Letter of Intent to sell its midstream business and transportation assets of CPE Gathering MidCon, LLC ("CPE Gathering") to Olenox Industries, Inc. (NASDAQ:OLOX) for approximately $36 million. Vivakor is the owner and operator of the Omega pipeline system, an integrated crude-oil gathering, transportation, terminaling and pipeline connection platform serving the Oklahoma STACK play. The transaction, valued at approximately $36 million, will be paid i

    2/2/26 8:30:00 AM ET
    $OLOX
    $VIVK
    RETAIL: Building Materials
    Consumer Discretionary
    Environmental Services
    Utilities

    Velocity Financial, Inc. Announces Date of Fourth Quarter and Full Year 2025 Financial Results Webcast and Conference Call

    Velocity Financial, Inc. (NYSE:VEL) ("Velocity" or "Company"), a leader in investor real estate loans, will release its fourth quarter and full year 2025 results after the market close on Wednesday, March 11, 2026. Velocity's executive management team will host a conference call and webcast to review its financial results at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on the same day. Webcast Information The conference call will be webcast live in listen-only mode and can be accessed through the Events and Presentations section of the Company's Investor Relations website at https://www.velfinance.com/events-and-presentations. To join the webcast, please go to Velocity's website at l

    1/29/26 8:35:00 AM ET
    $VEL
    Finance: Consumer Services
    Finance

    Olenox Industries Signs Letter of Intent to Acquire Vivakor's Midstream Business in Oklahoma STACK Play

    CONROE, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- via IBN -- Olenox Industries Inc. (NASDAQ:OLOX) ("Olenox Industries" or the "Company"), today announced that it has executed a non-binding Letter of Intent to acquire the midstream business and transportation assets of CPE Gathering MidCon, LLC ("CPE Gathering") from Vivakor, Inc. (OTC:VIVK), owner and operator of the Omega pipeline system, an integrated crude-oil gathering, transportation, terminaling and pipeline connection platform serving the Oklahoma STACK play.   The transaction, valued at approximately $36 million, will be paid in a combination of cash, promissory note, common and preferred stock, and is based on $4.56 million in ann

    1/29/26 8:30:00 AM ET
    $OLOX
    $VIVK
    RETAIL: Building Materials
    Consumer Discretionary
    Environmental Services
    Utilities